Bris­tol My­er­s' Op­di­vo-Yer­voy beats Lenvi­ma and Nex­avar in Phase 3 ear­ly liv­er can­cer tri­al

Bris­tol My­ers Squibb’s Op­di­vo and Yer­voy com­bo could be­come the new stan­dard of care in first-line un­re­sectable he­pa­to­cel­lu­lar car­ci­no­ma (uHCC) ac­cord­ing to Phase 3 da­ta …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.